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The dopamine transporter is a key protein responsible for regulating dopamine homeostasis. Its 
function is to transport dopamine from the extracellular space into the presynaptic neuron. Studies 
have suggested that accumulation of dopamine in the cytosol can trigger oxidative stress and 
neurotoxicity. Previously, ectopic expression of the dopamine transporter was shown to cause 
damage in non-dopaminergic neurons due to their inability to handle cytosolic dopamine. 
However, it is unknown whether increasing dopamine transporter activity will be detrimental to 
dopamine neurons that are inherently capable of storing and degrading dopamine. To address this 
issue, we characterized transgenic mice that over-express the dopamine transporter selectively in 
dopamine neurons. We report that dopamine transporter over-expressing (DAT-tg) mice display 
spontaneous loss of midbrain dopamine neurons that is accompanied by increases in oxidative 
stress markers, 5-S-cysteinyl-dopamine and 5-S-cysteinyl-DOPAC. In addition, metabolite-to-
dopamine ratios are increased and VMAT2 protein expression is decreased in the striatum of these 
animals. Furthermore, DAT-tg mice also show fine motor deficits on challenging beam traversal 
that are reversed with L-DOPA treatment. Collectively, our findings demonstrate that even in 
neurons that routinely handle dopamine, increased uptake of this neurotransmitter through the 
dopamine transporter results in oxidative damage, neuronal loss and LDOPA reversible motor 
deficits. In addition, DAT over-expressing animals are highly sensitive to MPTP-induced 
neurotoxicity. The effects of increased dopamine uptake in these transgenic mice could shed light 
on the unique vulnerability of dopamine neurons in Parkinson’s disease.
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INTRODUCTION
Malfunction of the dopamine system is implicated in several disease states including 
schizophrenia, addiction and Parkinson’s disease (PD) (Howes and Kapur, 2009; Volkow et 
al., 2007; Fahn 2003). In particular, PD is characterized by a profound loss of nigrostriatal 
dopamine neurons leading to reduced dopamine levels in the basal ganglia (Fahn 2003). One 
of the key proteins involved in regulating dopaminergic tone is the dopamine transporter 
(DAT). DAT is located on the cell membrane of dopaminergic neurons and functions to 
rapidly take up dopamine from the extracellular space into the presynaptic neuron. DAT not 
only controls the magnitude and duration of extracellular dopamine signaling, but also acts 
to maintain intracellular dopamine levels. In DAT knock-out (DAT-KO) mice, stored 
dopamine levels are reduced by 95% despite an increase in the rate of dopamine synthesis 
(Giros et al., 1996; Jones et al., 1998). This dramatic decrease in dopamine tissue content is 
largely due to lack of uptake since the number of dopaminergic neurons in DAT-KO mice 
are mostly preserved (Giros et al., 1996; Jaber et al., 1999). These findings from DAT-KO 
animals highlight the critical role of DAT in loading the presynaptic neuron with dopamine, 
which has important physiological consequences.
Indeed, if cytosolic dopamine is not appropriately sequestered into vesicles, it can produce 
reactive oxygen species, quinones and toxic intermediates through metabolism, autoxidation 
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and enzyme-dependent reactions (Stokes et al., 1999; Graham et al., 1978; Ramkissoon and 
Wells, 2011; Goldstein et al., 2012). Several studies have shown that intracellular 
accumulation of dopamine can lead to oxidative stress and neurotoxicity. For instance, direct 
injection of dopamine into the rat striatum resulted in loss of dopaminergic cells - an effect 
that was rescued by antioxidant co-injection (Hastings et al., 1996). Notably, Mosharov et 
al. (2009) demonstrated that cytosolic dopamine levels directly impact toxicity in cultured 
midbrain neurons. They showed that blocking dopamine degradation led to accumulation of 
cytosolic dopamine and caused neurotoxicity, whereas inhibiting the conversion of L-3,4-
dihydroxyphenylalanine (L-DOPA) to dopamine, reduced cytosolic dopamine levels and 
prevented neurotoxicity (Mosharov et al., 2009). Additionally, over-expression of vesicular 
monoamine transporter 2 (VMAT2), a protein that sequesters intracellular dopamine into 
vesicles and reduces cytosolic dopamine levels, has been shown to have protective effects 
against neuronal damage both in cultured midbrain neurons and mice (Mosharov et al., 
2009; Lohr et al., 2014). Conversely, we have previously reported that genetic knockdown 
of VMAT2 in mice leads to oxidative stress and progressive degeneration of nigrostriatal 
neurons (Caudle et al., 2007). These studies suggest that amplifying the cytosolic pool of 
dopamine can aggravate oxidative damage and negatively impact neuronal survival.
In a previous study, Chen et al. (2008) showed that ectopic expression of DAT in 
GABAergic striatal neurons leads to progressive cell loss and oxidative protein 
modifications. These results indicated that ectopic DAT expression in non-dopaminergic 
neurons is deleterious since these cells do not possess the capacity to efficiently metabolize 
or store dopamine in vesicles. In the current study, we investigated whether increased DAT-
mediated uptake of dopamine can produce damage in dopaminergic cells that routinely 
handle this neurotransmitter and are equipped to sequester and degrade it. In particular, we 
used bacterial artificial chromosome (BAC) transgenic mice that selectively over-express 
DAT in dopaminergic cells (DAT-tg mice, Salahpour et al., 2008). Previously, we reported 
that total DAT protein levels were increased in DAT-tg mice and expression of DAT was 
restricted to dopaminergic neurons (Salahpour et al., 2008). Functionally, transgenic animals 
showed a 46% increase in the rate of dopamine uptake and a 40% decrease in extracellular 
dopamine levels, which led to up-regulation of post-synaptic dopamine receptors (Salahpour 
et al., 2008; Kile et al., 2012; Calipari et al., 2013; Ghisi et al., 2009).
Here we determined the effects of increased DAT expression on dopamine homeostasis, 
neuronal survival, oxidative stress and motor behavior of DAT-tg mice. We also evaluated 
the response these animals to the PD-inducing neurotoxin, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) (Langston et al., 1983). Our results demonstrate that DAT-tg 
mice have 30-36% loss of midbrain dopamine neurons that is accompanied by evidence of 
oxidative stress. These animals also show fine motor deficits that are reversed by L-DOPA, 
the main treatment for motor symptoms of PD. In addition, DAT-tg mice are particularly 
vulnerable to dopaminergic damage induced by MPTP. These findings demonstrate that 
even in dopaminergic cells that endogenously express DAT, an increase in DAT-mediated 
uptake of dopamine leads to basal neurotoxicity and heightened sensitivity to exogenous 
insults.
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Generation of DAT-tg mice using BAC transgenesis has been described in Salahpour et al., 
2008. Briefly, transgenic animals were created by pronuclear injection of a BAC containing 
the DAT locus and 80kb of upstream and downstream genomic sequences. Adult (3-5 month 
old) DAT-tg mice and their wild-type (WT) littermates (C57BL/6J background) were age 
and sex-matched across groups. All experiments were conducted in accordance with the 
Canadian Council on Animal Care and approved by the Faculty of Medicine Animal Care 
Committee at the University of Toronto.
Western blots
Western blots were used to quantify DAT, VMAT2, TH, GAPDH and α-tubulin protein 
expression in striatal tissue. Western blots were performed as previously described (Caudle 
et al., 2007; Salahpour et al., 2008). For DAT and its corresponding loading control, 
GAPDH, striatal tissue (pooled from 6 mice per sample) was homogenized in 320mM 
sucrose, 4mM HEPES buffer with protease and phosphatase inhibitors. These homogenized 
samples were then used to analyze protein concentration (BCA protein assay, Pierce). For 
TH and α-tubulin, striatal tissue was mechanically homogenized in RIPA buffer with 
protease inhibitors. Samples were centrifuged at 15,000rpm for 15 minutes and the 
supernatant was used to analyze protein concentration (BCA protein assay, Pierce). For 
VMAT2 and its corresponding loading control, GAPDH, striatal tissue was mechanically 
homogenized in 320mM sucrose, 5mM HEPES buffer with protease inhibitors. 
Homogenized samples were centrifuged at 3500rpm for 5 minutes and the supernatant was 
again centrifuged at 14,000rpm for 1 hour. The pellet was resuspended in homogenization 
buffer and used analyze protein concentration (BCA protein assay, Pierce).
Protein extracts (20-30ug) were separated by 8.5% or 10% SDS/PAGE and transferred onto 
polyvinylidene difluoride membranes. Nonspecific binding was blocked using either 5-7.5% 
milk (TH, VMAT2 and corresponding loading controls) or Rockland blocking buffer (DAT 
and GAPDH loading control). Immunoblots were incubated overnight at 4°C with the 
following primary antibodies: rat anti-DAT (1:750, Millipore) rabbit anti-TH (1:3000, 
Millipore), mouse anti-GAPDH (1:4000, Sigma), rabbit anti-VMAT2 (1:20,000, obtained 
from Miller lab, Lohr et al., 2014) and mouse anti-α-tubulin (1:2000, Hybridoma Bank). 
Appropriate secondary antibodies (1:5000, Alexa Fluor 680 or IRDye 800CW, Rockland) 
were used and blots were developed using the LI-COR Odyssey Imaging System (LI-COR). 
Densitometric analysis of protein bands were performed using Image-J software (National 
Institutes of Health). GAPDH and α-tubulin immunoblots were used to normalize protein 
loading across samples.
HPLC with electrochemical detection
For measurement of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic 
acid (HVA), dissected striata were homogenized in 0.1M perchloric acid and centrifuged 
(9,400 × g for 10 min at 4°C). The supernatant was filtered through a 0.22μm membrane 
(Millipore). Samples were analyzed using a Hypersil Gold C18 column (150 × 3mm; 5μm; 
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Thermo Scientific) and a LC-4C Amperometric Detector (BASi) set at an oxidizing 
potential of +0.75V. The mobile phase contained 24mM Na2HPO4, 3.6mM 1-octanesulfonic 
acid, 30mM citric acid, 0.14mM EDTA in 19% methanol, adjusted to pH 4.7 using 
concentrated NaOH. 5-S-Cysteinyl-dopamine and 5-S-cysteinyl-DOPAC were measured as 
described previously (Hatcher et al., 2007; Caudle et al., 2007). Briefly, striatal samples 
were sonicated in 0.1M perchloric acid containing 347μM sodium bisulfite and 134μM 
EDTA. Homogenates were centrifuged, filtered and separated on a C18 column. The 
electrochemical detector was set at an oxidizing potential of +0.65V. The mobile phase was 
MD-TM (ESA) containing 2mM NaCl and adjusted to pH 2.1 using concentrated HCl. 
Quantification of all neurochemicals was conducted by referring to calibration curves 
constructed from pure standards (purity >98%; dopamine, DOPAC and HVA from Sigma 
Aldrich; 5-S-cysteinyl-DA and 5-S-cysteinyl-DOPAC from NIMH Chemical Repository).
Fast-scan cyclic voltammetry (FSCV)
FSCV was performed according to Salahpour et al. 2008. Briefly, mice were anesthetized, 
decapitated, and coronal slices (300μm) from the striatum were cut and maintained in cold 
artificial cerebral spinal fluid (pH 7.4, 95% O2 / 5% CO2). Recordings were performed in a 
slice perfusion chamber at 37°C (Warner Instruments). DA release was electrically 
stimulated by biphasic (2ms/phase) constant-current (350μA) pulses via a tungsten bipolar 
electrode. The detector microelectrode was placed 75-100μm into the slice and 100-200μm 
away from the stimulating electrode. Release measurements were performed with and 
without 2β-propanoyl-3β-(4-tolyl)-tropane (PTT, 200nM, applied for 35mins).
Stereology
Mice were perfused with 4% paraformaldehyde. Brains were removed, stored in 10% 
sucrose/ 4% paraformaldehyde and coronally sectioned (60μm) with a Leica CM3050S 
cryostat (Leica). Coronal brain sections containing the substantia nigra and the ventral 
tegmental area (−2.92 to −3.64 mm from the bregma; Paxinos and Franklin, 2001) were kept 
at 4°C in phosphate buffered saline (PBS) and processed for free-floating 
immunofluorescence. Sections were incubated in permeabilizing solution containing 1.2% 
Triton X-100 in PBS followed by blocking solution containing 10% normal goat serum in 
PBS to avoid non-specific binding. Sections were then incubated with primary antibodies 
(rabbit anti-TH, 1:500; mouse anti-NeuN, 1:200, Millipore), secondary antibodies 
(fluorescein (FITC)-conjugated goat anti-mouse IgG, 1:500; DyLight 594-conjugated goat 
anti-rabbit IgG, 1:500; Jackson ImmunoResearch Laboratories) and Hoechst 33342 
(1:10,000 in PBS, Invitrogen). Sections were mounted in Vectashield medium (Vector 
Laboratories) on Superfrost slides for visualization under a confocal spinning disk 
microscope (Olympus).
Number of NeuN and TH-positive cells in the SNc or VTA were determined by unbiased 
stereological quantification using the optical fractionator of Stereo Investigator software 
(MBF Bioscience). Five coronal sections containing the SNc and VTA were considered per 
animal: −2.92, −3.10, −3.28, −3.46 and −3.64 mm from the bregma (Paxinos and Franklin, 
2001). Borders of the SNc or VTA were determined by TH-immunostaining using 2X 
objective. Cells were counted with a 60X PlanApo oil-immersion objective and 1.4 
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numerical aperture attached to an Olympus BX51 microscope. A systematic sampling of the 
outlined area was made from a random starting point. Counts were made at predetermined 
intervals (x = 250, y = 150) and a counting frame (50 μm × 50 μm) was superimposed on 
live images of the brain sections. Section thickness was measured by focusing on the top of 
the section, zeroing the z-axis and focusing on bottom of the section (average section 
thickness was 60 μm with a range of 58.9 – 61.1 μm). The dissector height was set at 50 μm. 
Immunoreactive neurons were only counted if the recognizable profile came into focus 
within the counting frame. This method certified a uniform, random and systematic cell 
count. Focusing through the z-axis revealed that NeuN and TH antibodies penetrated the full 
depth of tissue sections.
Behavioral assessments
Baseline motor behavior of untreated animals was assessed using open field locomotion, 
stereotypy and wire-hang test. Open field locomotor activity and stereotypy were measured 
using the VersaMax Animal Activity Monitoring System (Omnitech Electronics). Mice were 
placed in acrylic chambers (20cm × 20cm × 45cm) and infrared light sensors were used to 
track movement. Locomotor activity was measured as total distance traveled. Stereotypic 
behavior was detected when the animal broke the same beam or set of beams repeatedly. 
Total distance traveled and stereotypy counts were recorded in five minute intervals over a 
two hour period. The wire-hang test was conducted by placing a mouse on a wire cage lid 
and shaking the lid slightly to make the animal grip the wires. Then the lid was inverted and 
suspended above a clean cage containing bedding. The latency of the mouse to fall off the 
grid was measured. Trials were stopped if the mouse remained on the lid for over 10 
minutes. Average values were calculated from two trials (at least 15 minutes apart).
For challenging beam traversal, the effect of L-DOPA treatment on motor ability was 
evaluated. The challenging beam traversal was conducted as previously described by 
Fleming et al., 2004. Animals were trained to traverse the length of a Plexiglas beam 
consisting of four sections (25 cm each, 1 m total length) decreasing in width from 3.5 cm to 
0.5 cm by 1 cm increments. Untreated mice were trained for two days to traverse the beam 
that led to the animal’s home cage. On the third day (test day), a mesh grid (1 cm squares) of 
corresponding width was placed over the beam surface. A space of approximately 1 cm 
separated the grid from the surface of the beam. On the test day, animals were treated with 
12.5 mg/kg of benserazide (i.p.), followed 20 minutes later by 25 mg/kg of L-DOPA (i.p.). 
In the control group, animals received two 0.9% saline injections separated by 20 minutes. 
Testing on the challenging beam began 10 minutes after the second injection. This treatment 
regimen has previously been used to assess L-DOPA effects on challenging beam motor 
behavior (Hwang et al., 2005). Animals were videotaped while traversing the grid-surfaced 
beam over three trials. Video was viewed in slow motion to detect 1) errors including paw 
slips through the mesh-grid and paws placed on the side rather the top of the grid during 
forward motion and 2) steps taken to traverse the beam. Errors per step were calculated and 
time to traverse the beam was also recorded. Number of errors, number of steps, errors per 
step and time to traverse the beam were quantified per trial and averaged over three trials for 
each animal.
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All baseline motor behaviors were tested in both males and females. Sex-stratified results 
are shown in Supplementary Figure 1.
MPTP treatment
MPTP hydrochloride (Sigma Aldrich) was dissolved in PBS and administered (i.p. 0.1ml/g 
body weight) twice, 10 hours apart, at a dose of 15 or 30 mg/kg of body weight. Animals 
were sacrificed after seven days and brains were harvested for toxicity analyses.
Immunohistochemistry
Mice were perfused using 4% paraformaldehyde. Brains were removed, stored in 30% 
sucrose and coronally sectioned (50μm, Leica cryostat). Striatal sections were incubated 
with primary rabbit anti-TH antibody (1:500, Millipore) and appropriate secondary antibody 
(1:5000, Rockland Inc.). Immunofluorescence was visualized using the LI-COR Odyssey 
Imaging System (LI-COR).
Statistics
Data shown are means ± SEM. Data were statistically analyzed by two tailed t-tests, one-
way ANOVA with Bonferroni post hoc tests, or two-way ANOVA with Bonferroni post hoc 
tests, as appropriate. GraphPad Prism and SPSS software were used for graphs and statistical 
analyses. Significance is reported at p<0.05.
RESULTS
Altered dopamine homeostasis in DAT-tg mice
First, we confirmed over-expression of DAT protein in the striatum of DAT-tg mice using 
western blots (p< 0.05, Fig. 1). Then, we investigated the effect of increased DAT 
expression on dopamine homeostasis by assessing dopamine tissue content in the striatum of 
transgenic animals. DAT-tg mice showed a 33% reduction in dopamine tissue levels in 
comparison to wild-type (WT) animals (p< 0.05, Fig. 2A). To confirm this decrease in 
dopamine tissue content, we measured the electrically-evoked release of dopamine from 
striatal slices. The amount of dopamine released was reduced by 72% in striatal slices from 
DAT-tg animals (p< 0.001, Fig. 2B). To eliminate the confounding effect of enhanced 
dopamine uptake in DAT-tg mice, the dopamine release experiments were repeated in the 
presence of 2β-propanoyl-3β-(4-tolyl)-tropane (PTT), a quasi-irreversible DAT blocker 
(Bennett et al., 1995). Even with DAT blockade, there was a 46% reduction in dopamine 
release in DAT-tg mice (p< 0.001, Fig. 2B), which is in line with the lower dopamine tissue 
content observed in these animals. Next, we assessed dopamine metabolism in the striatum 
by measuring tissue levels of 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic 
acid (HVA), the major metabolites of dopamine. DAT-tg animals showed a 60% increase in 
the DOPAC/dopamine ratio (p< 0.01, Fig. 2C) and a 38% increase in the HVA/dopamine 
ratio (p< 0.01, Fig. 2D), suggesting a higher turnover of dopamine in these animals.
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Spontaneous loss of midbrain dopamine neurons and increased oxidative stress in DAT-tg 
mice
The reductions in dopamine tissue content (Fig. 2A) and release (Fig. 2B) could indicate 
compromised integrity of dopamine neurons in DAT-tg mice. To verify if these changes 
resulted from dopaminergic cell loss, we performed stereological counts of dopamine 
neurons in two major dopaminergic centers of the midbrain: 1) the substantia nigra pars 
compacta (SNc) and 2) the ventral tegmental area (VTA) (Fig. 3A). Using NeuN as a 
general neuronal marker, a 32% reduction in the overall number of neurons was observed in 
the SNc of DAT-tg mice (p< 0.01, Fig. 3B). Tyrosine hydroxylase (TH) was used as a 
specific marker of dopamine neurons and a 36% loss of TH-positive cells was detected in 
the SNc of transgenic animals (p< 0.01, Fig. 3B). In the VTA, the numbers of NeuN- and 
TH-immunoreactive neurons were reduced by 30% and 28% respectively, in DAT-tg 
animals (NeuN, p< 0.05; TH p< 0.01, Fig. 3C). These results indicate that increased DAT 
activity leads to loss of dopaminergic neurons in the midbrain.
Since previous studies have suggested that cytosolic dopamine is highly reactive and can 
induce oxidative stress, we investigated whether the neuronal death in DAT-tg mice might 
be associated with increased oxidative damage (Graham et al., 1978; Stokes et al., 1999; 
Hastings et al., 1996). The formation of cysteinyl adducts on dopamine and its metabolites 
are indicative of oxidative damage occurring specifically within dopaminergic neurons 
(Graham et al., 1978; Fornstedt and Carlsson, 1989; Hastings and Zigmond, 1994). 
Therefore, we measured 5-S-cysteinyl-dopamine and 5-S-cysteinyl-DOPAC tissue content 
as markers of oxidative stress in the striatum of DAT-tg mice. Despite a reduction in overall 
dopamine tissue levels (Fig. 2A), DAT-tg mice exhibit a 35% increase in 5-S-cysteinyl-
dopamine (p< 0.05, Fig. 4A), in addition to a 62% increase in 5-S-cysteinyl-DOPAC levels 
(p< 0.01, Fig. 4B). Elevated tissue content of cysteinyl-dopamine and cysteinyl-DOPAC 
suggests that oxidative stress may underlie the dopaminergic cell loss observed in these 
mice.
Evidence of dopaminergic oxidative stress in DAT-tg mice implicates cytosolic dopamine as 
a potential source of oxidative damage. Aside from DAT-mediated uptake of dopamine, 
another important regulator of dopamine accumulation in the cytosol is VMAT2-mediated 
vesicular storage. Therefore, we evaluated VMAT2 protein levels in the striatum of DAT-tg 
mice. As shown in Figure 5, transgenic animals displayed lower VMAT2 protein levels (p< 
0.01), suggesting that reduced vesicular storage could contribute to buildup of cytosolic 
dopamine in these animals.
Fine motor deficits in DAT-tg mice are reversed by L-DOPA treatment
Since the nigrostriatal dopamine pathway is heavily involved in controlling motor activity 
(Albin et al., 1989; Zhou and Palmiter, 1995), we assessed whether dopaminergic cell loss in 
DAT-tg mice had any influence on their baseline motor behavior. First, we measured open-
field locomotion for two hours and found no changes in total distance traveled (Fig. 6A) or 
stereotypy (Fig. 6B) in DAT-tg mice. Next, animals were assessed using the wire-hang test, 
a measure of motor strength in rodent models (Luk et al., 2012; Oaks et al., 2013). DAT-tg 
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mice showed a 36% decrease in the latency to fall off the wire (p< 0.05, Fig. 6C), 
demonstrating compromised motor ability.
Furthermore, we evaluated the effects of L-DOPA treatment on the motor behavior of 
animals using the challenging beam traversal. This task is particularly sensitive to motor 
deficits that arise from nigrostriatal dopamine dysfunction (Drucker-Colín et al., 1991; 
Fleming et al., 2004). Saline-treated DAT-tg mice showed a 50% increase in number of 
errors (slips and misplaced paws) and a 47% increase in errors per step while traversing the 
beam (p< 0.01, Fig. 7A and p< 0.01, Fig. 7C, respectively). However, when treated with L-
DOPA, DAT-tg animals performed significantly better as demonstrated by decreased errors, 
fewer steps taken and lower errors per step in comparison to saline-treated transgenic mice 
(p< 0.01, Fig. 7A; p< 0.05, Fig. 7B and p< 0.05, Fig. 7C, respectively). Across all groups, 
there were no differences in time to traverse the beam (Fig. 7D). Collectively, results from 
these behavioral tests indicate that although DAT-tg mice do not show any changes in gross 
locomotion, they display significant deficits in fine motor coordination that can be reversed 
with L-DOPA treatment.
DAT-tg mice are highly sensitive to MPTP-induced dopaminergic toxicity
Sensitivity of DAT-tg mice to exogenous toxicant insult was measured using two doses of 
MPTP, 15 and 30 mg/kg of body weight. We evaluated dopaminergic damage in the 
striatum by investigating expression of TH, a marker of dopaminergic cells. TH protein 
expression was assessed qualitatively by immunohistochemistry (Fig. 8A) and quantitatively 
by western blots (Fig. 8B,C). At 15 mg/kg of MPTP, DAT-tg mice displayed lower TH 
immunofluorescence (Fig. 8A) and protein levels (p< 0.05, Fig. 8C) than WT animals (Fig. 
8A,B). Indeed, in WT mice, this dose of MPTP did not elicit any significant change in TH 
immunoreactivity (Fig. 8A) or protein levels (Fig. 8B) when compared to saline treatment. 
At 30mg/kg of MPTP, TH immunofluorescence was decreased in both WT and DAT-tg 
mice (Fig. 8A) however, the extent of reduction was greater in DAT-tg mice as quantified 
by western blot analysis (Fig. 8B,C). In particular, TH levels were reduced by 65% in 
transgenic animals (p< 0.001, Fig. 8C) in contrast to only 28% in WT animals (p< 0.01, Fig. 
8B), when compared to saline treatment. These results demonstrate that DAT-tg mice are 
more vulnerable to MPTP treatment and exhibit sensitivity at doses that do not significantly 
affect WT animals.
Next, striatal dopamine tissue content was measured to assess the integrity of dopaminergic 
nerve terminals in MPTP-treated mice. At both 15 and 30 mg/kg of MPTP, the respective 
reductions in dopamine tissue content were greater in DAT-tg mice compared to WT 
controls, indicating that increased DAT levels exacerbate MPTP-induced neurotoxicity (15 
mg/kg MPTP, p< 0.05; 30 mg/kg MPTP, p< 0.01; Fig. 9). A difference in striatal dopamine 
content was also detected between saline-treated WT and DAT-tg mice (p< 0.01, Fig. 9), 
corroborating the basal reduction in dopamine tissue levels previously observed in untreated 
transgenic animals (Fig. 2A).
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In this study, we report that over-expression of DAT is capable of triggering oxidative 
stress, dopamine neuron loss and L-DOPA reversible motor deficits in DAT-tg mice. 
Previously, ectopic expression of DAT was shown to cause death of non-dopaminergic cells, 
presumably due to their inability to properly handle cytotoxic dopamine (Chen et al., 2008). 
However, we demonstrate that even in dopamine cells that are inherently equipped with the 
molecular machinery to properly store, metabolize and release dopamine, an increase in 
DAT expression can lead to higher dopamine uptake and damaging consequences. Aside 
from our work, previous studies using plasmid and lentiviral techniques have also reported 
that DAT over-expression can increase dopamine uptake and alter downstream behaviors 
(Martres et al., 1998, Adriani et al., 2009). Transgenic mice expressing DAT under the TH 
promoter showed higher DAT levels, greater dopamine uptake and modest, but significant 
reductions in striatal dopamine tissue content (Donovan et al., 1999), similar to DAT-tg 
mice. In comparison to these studies, our BAC transgenic approach to over-express DAT 
has several important advantages including: 1) robust, long-term DAT expression, 2) 
selectivity for dopaminergic neurons using the DAT promoter and 3) lack of injection and 
transfection-related complications. Collectively, this body of work shows that increased 
DAT activity can significantly impact and change dopamine homeostasis.
The dopamine system is notoriously sensitive to endogenous and exogenous challenges 
(Hastings et al., 1996; Mosharov et al., 2009; Langston et al., 1983). Therefore, 46% higher 
dopamine uptake in DAT-tg mice (Salahpour et al., 2008) produces dramatic effects on 
dopamine homeostasis, cell survival, oxidative stress and motor behaviors, as noted in this 
study. These results highlight the physiological importance of tightly regulating cytosolic 
dopamine levels since moderate deviations in dopamine compartmentalization can directly 
impact neuronal survivability. Another example of this is the VMAT2-knockdown 
(VMAT2-kd) mice. These animals express only 5% of normal VMAT2 protein and display 
decreased dopamine tissue content, nigrostriatal neurodegeneration and increased levels of 
cysteinyl-catechols (Caudle et al., 2007), similar to DAT-tg mice. Physiologically, VMAT2-
kd mice are deficient in sequestering intracellular dopamine into vesicles while DAT-tg 
mice have excess dopamine uptake (Caudle et al., 2007; Salahpour et al., 2008). In addition 
to higher uptake, DAT-tg mice also have reduced VMAT2 expression, suggesting that 
vesicular storage of dopamine could also be compromised. Taken together, the genetic 
manipulations in VMAT2-kd and DAT-tg mice effectively act to increase the cytosolic pool 
of dopamine. This buildup of cytosolic dopamine could be a common pathway that is 
responsible for the basal loss of dopamine neurons and oxidative stress evident in both 
VMAT2-kd and DAT-tg mice.
There are several observations supporting the hypothesis that accumulation of cytosolic 
dopamine results in loss of dopaminergic neurons in DAT-tg mice. First, results from DAT-
KO animals highlight the critical role of DAT in loading the presynaptic neuron with 
dopamine (Giros et al., 1996; Jones et al., 1998; Sotnikova et al., 2005). In DAT-KO mice, 
lack of uptake leads to 5-times higher extracellular dopamine levels and extremely low 
dopamine tissue content (5%), indicating depleted intracellular stores. Conversely, in DAT-
tg mice, higher levels of functional DAT leads to a 46% increase in dopamine uptake and a 
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40% decrease in extracellular dopamine, suggesting that the neurotransmitter is 
accumulating in the presynaptic neuron (Salahpour et al., 2008). However, despite the likely 
buildup of dopamine within each dopaminergic cell, DAT-tg mice display a 33% reduction 
in overall dopamine tissue content as a direct consequence of 30-36% loss of dopamine 
neurons. Secondly, we report higher metabolite-to-dopamine ratios in DAT-tg mice. Since 
DOPAC is a direct product of cytosolic dopamine metabolism, a 60% increase in the 
DOPAC/dopamine ratio could indicate that a greater proportion of dopamine is present in 
the cytosol and not sequestered into vesicles (Di Monte et al., 1996). Elevated metabolite-to-
dopamine ratios also imply enhanced dopamine turnover that could be a compensatory 
mechanism to tackle the buildup of intracellular DA (Zigmond et al., 2002). Thirdly, 
increased levels of 5-S-cysteinyl-dopamine and 5-S-cysteinyl-DOPAC were detected in the 
striatum of DAT-tg mice. These cysteinyl-modified adducts have been suggested to arise 
from the oxidation of cytosolic dopamine and its metabolites (Hastings and Zigmond, 1994; 
Fornstedt and Carlsson, 1989; Graham et al., 1978). Not only are cysteinyl adducts a direct 
consequence of cytosolic dopamine reactivity, they are also capable of independently 
inducing further neuronal damage (Spencer et al., 2002). Next, lower VMAT2 protein 
expression in DAT-tg mice also suggests potential buildup of cytosolic dopamine. Although 
this decrease may be a reflection of dopaminergic cell loss per se, nonetheless, reduced 
VMAT2 levels can negatively impact vesicular storage, thus disabling these mice from 
handling increased dopamine uptake from DAT over-expression. Lastly, accumulation of 
cytosolic dopamine has been suggested to have deleterious effects on cell survival (Chen et 
al., 2008; Caudle et al., 2007, Mosharov et al., 2009) that is clearly reflected in the loss of 
dopamine neurons in DAT-tg mice. Collectively, these observations suggest that DAT over-
expression most likely leads to high cytosolic levels of dopamine, thereby producing the 
downstream detrimental effects observed in DAT-tg mice.
We also demonstrated that DAT-tg mice are highly sensitive to MPTP-induced 
neurotoxicity. Indeed, when treated with MPTP, DAT-tg mice showed greater reductions in 
striatal TH levels and dopamine tissue content compared to WT animals. MPP+, the toxic 
metabolite of MPTP, is a substrate for DAT and therefore, causes selective damage to 
dopaminergic cells (Gainetdinov et al., 1997; Langston et al., 1984; Chiba et al., 1985; 
Ramsay et al., 1986; Schober et al., 2004). While the dependence of MPTP neurotoxicity on 
DAT function has previously been demonstrated (Gainetdinov et al., 1997; Bezard et al., 
1999, Miller et al., 1999; Schober 2004), our results indicate a synergistic interaction 
between environmental and genetic risk factors that could have broader implications for 
complex pathological conditions such as PD (Cannon and Greenamyre, 2013). In PD, both 
genetic mutations and environmental conditions have been documented to increase disease 
risk (Hardy et al., 2006; Priyadarshi et al., 2000; Cannon and Greenamyre, 2013; Bezard et 
al., 2013; Martin et al., 2011). Moreover, animal models that depend on a single type of 
insult seldom recapitulate the full spectrum of the disorder (Beal, 2010). Although genes 
such as PINK1, DJ1 and PARK2 (parkin) have been implicated in familial forms of PD, 
mutating or knocking-out these essential genes in most animal models does not reproduce 
dopaminergic cell loss (Gispert et al., 2009; Yamaguchi and Shen, 2007; Goldberg et al., 
2003). Conversely, while acute toxicant treatment (e.g. MPTP or 6-hydroxydopamine) can 
produce abrupt neurodegeneration, it does not address the underlying disease mechanism of 
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a chronic and progressive disorder like PD (Schober 2004). Given the shortcomings of these 
individual approaches, the convergence of genetic as well as environmental insults may be 
more representative of idiopathic PD that is hypothesized to arise from multiple hits 
(Cannon and Greenamyre, 2013; Sulzer, 2007). Our results lend support to this idea by 
showing that genetic over-expression of DAT combined with exogenous exposure to MPTP, 
aggravates toxicity to dopamine neurons. Although the effect of genetic mutations on DAT 
expression is unclear in humans, a correlation study reports that DAT genetic variants in 
combination with exposure to exogenous compounds ( e.g. pesticides) can potentiate the risk 
of developing PD by 3 or 4 fold (Ritz et al., 2009). This highlights the significance of 
genetic and environmental interactions in the pathology of PD.
The cellular, neurochemical and behavioral changes observed in DAT-tg mice recapitulate 
important features of PD. Firstly, loss of midbrain dopamine neurons and reduced dopamine 
tissue content in the striatum of DAT-tg mice capture the major pathological characteristics 
of PD (Dauer and Przedborski, 2003). However, it should be noted that PD is characterized 
by selective nigrostriatal degeneration, whereas DAT-tg mice also demonstrate loss of VTA 
dopamine neurons. This is probably due to transgenic over-expression of DAT in the VTA, 
which enhances the vulnerability of this region in DAT-tg mice. Physiologically, VTA 
neurons do not express as much DAT as SNc neurons and therefore, the VTA is relatively 
spared from damage in PD (Blanchard et al., 1994). The relationship between DAT 
expression and neurodegeneration is supported by a study in PD patients showing that brain 
regions containing the highest levels of DAT protein – the caudate and putamen – are also 
the most sensitive to damage (Miller et al., 1997). In addition, a recent meta-analysis has 
identified the DAT gene as a risk factor for PD in certain populations (Zhai et al., 2014). 
Secondly, oxidative stress has long been postulated to be involved in the development of PD 
(Fahn and Cohen, 1992) and we report that DAT-tg mice display increased levels of 
cysteinyl-dopamine and cysteinyl-DOPAC, two markers that are also elevated in the SN of 
PD patients (Spencer et al., 1998). Thirdly, increased dopamine turnover in the transgenic 
mice mirrors elevated metabolite-to-dopamine ratios that have been reported in PD patients 
(Zigmond et al., 2002; Rabey and Burns, 2002). In addition, both DAT-tg mice and PD 
patients show reductions in VMAT2 protein expression in comparison to control samples 
(Miller et al., 1999). Behaviorally, DAT-tg mice do not exhibit any deficits in gross 
locomotion, probably because the level of cell loss in these animals is not sufficient to cause 
major motor disturbances. In PD patients, motor deficits are only evident when greater than 
70% of dopaminergic tone is lost in the striatum (Bernheimer et al., 1973). However, results 
from the wire-hang test and challenging beam traversal clearly demonstrate that fine motor 
coordination, balance and strength are compromised in DAT-tg mice similar to PD patients. 
Other studies on dopaminergic dysfunction have shown that these two tests are sensitive to 
motor impairment even in the absence of gross locomotor changes (Hwang et al., 2005; Luk 
et al, 2011). Furthermore, not only do DAT-tg mice display motor disturbances on the 
challenging beam traversal; these deficits are also reversed by L-DOPA, the principal 
treatment for motor symptoms of PD. This suggests that dopamine neuronal loss in DAT-tg 
mice leads to motor deficits that can be reversed by restoring dopaminergic tone. Hence, 
parallel to PD patients, DAT-tg mice also demonstrate motor behaviors that are responsive 
to L-DOPA treatment. Given these overlapping results, we postulate that the mishandling of 
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cytosolic dopamine exhibited by DAT-tg mice could provide important insights on the 
unique vulnerability of dopamine cells in PD.
In conclusion, we used transgenic mice that selectively over-express DAT in dopaminergic 
neurons to investigate the effects of cytosolic dopamine accumulation in vivo. As shown by 
our results, moderate increases in DAT function cause spontaneous dopaminergic cell loss, 
oxidative stress and fine motor impairment that is reversed by L-DOPA treatment. These 
results suggest that the integrity of dopamine neurons depends heavily on the ability of DAT 
to maintain proper homeostatic control of presynaptic dopamine. Since dopaminergic cells 
are selectively damaged by a broad variety of genetic and environmental insults, it 
demonstrates that these cells are inherently at risk. Our results imply that buildup of 
cytosolic dopamine, a highly reactive and potentially toxic molecule, may underlie the cell-
specific vulnerability of dopaminergic neurons to damage. We propose that dopamine 
uptake through DAT, maintains a constant cytosolic pool of this neurotransmitter that can 
propagate oxidative stress in dopamine cells. This type of chronic damage may render these 
neurons vulnerable to degeneration, especially if coupled with other genetic or 
environmental insults that are linked with the pathogenesis of PD. Since DAT-tg mice 
display spontaneous neuronal loss and heightened toxicity in response to MPTP, these mice 
provide a useful tool to study the effects of endogenous and exogenous challenges on 
dopamine cells.
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DAT-tg dopamine transporter over-expressing transgenic
DAT-KO dopamine transporter knock-out
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BAC bacterial artificial chromosome
FSCV fast-scan cyclic voltammetry
PTT 2β-propanoyl-3β-(4-tolyl)-tropane
TH tyrosine hydroxylase
SNc substantia nigra pars compacta
VTA ventral tegmental area
L-DOPA L-3,4-dihydroxyphenylalanine
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Dopamine transporter (DAT) over-expression leads to loss of midbrain dopamine 
neurons.
Neuronal loss is accompanied by oxidative stress and fine motor deficits.
Motor deficits on challenging beam traversal are reversed by L-DOPA treatment.
DAT transgenic mice are highly sensitive to MPTP-induced neurotoxicity.
Deleterious effects of DAT over-expression may be due to increased cytosolic dopamine.
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Over-expression of DAT protein in DAT-tg mice. DAT western blot and densitometry 
analysis of striatal tissue from WT and DAT-tg mice (pooled striata from 6 mice per sample, 
n=18 mice in total per genotype). DAT levels were corrected for loading using GAPDH and 
normalized to WT expression. Data shown are means ± SEM. * p<0.05.
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Altered dopamine homeostasis in DAT-tg mice. A- Striatal dopamine tissue content (n=7-9). 
B- Stimulated dopamine release assessed in brain slices in the absence or presence of PTT, a 
potent DAT blocker (n=4). C- Ratio of DOPAC-to-dopamine tissue content in the striatum 
(n=10-11). D- Ratio of HVA-to-dopamine tissue content in the striatum (n=10-11). Data 
shown are means ± SEM. * p<0.05, **p<0.01, ***p<0.001.
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Dopaminergic cell loss in the SNc and VTA of DAT-tg mice. A- Representative midbrain 
images double-labeled for NeuN (green) and TH (red). IF, immunofluorescence; SNc, 
substantia nigra pars compacta; SNr, substantia nigra pars reticulata; VTA, ventral tegmental 
area. Scale bar = 100 μm. Stereological counts of NeuN and TH-positive neurons are shown 
in the B- SNc and C- VTA. Significant differences (denoted by lines) are in comparison to 
corresponding WT animals. Data shown are means ± SEM (n= 3-7). *p<0.05 and **p<0.01.
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Increased markers of oxidative stress in the striatum of DAT-tg mice. HPLC quantification 
of A- 5-S-cysteinyl-dopamine and B- 5-S-cysteinyl-DOPAC tissue content in the striatum of 
WT and DAT-tg mice (n=9-10). Data shown are means ± SEM. *p<0.05, **p<0.01.
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Reduced VMAT2 protein expression in DAT-tg mice. VMAT2 western blot and 
densitometry analysis of striatal tissue from WT and DAT-tg mice (N=4). VMAT2-
knockdown (VMAT2-kd) samples were used as a negative control to identify the specific 
VMAT2 band. VMAT2 levels were corrected for loading using GAPDH and normalized to 
WT expression. Data shown are means ± SEM. **p<0.01.
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Locomotor behavior of DAT-tg mice. A- Total distance traveled and B- stereotypy counts 
from WT and DAT-tg mice tested in open field activity monitors for two hours (n=25-28). 
Stereotypy counts are defined as the number of beam breaks detected on the infrared 
monitor during stereotypic behavior. C- Average latency of mice to fall off the wire in the 
wire-hang test (n=37-40). Data shown are means ± SEM. *p<0.05.
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Challenging beam deficits in DAT-tg mice are reversed by L-DOPA administration. 
Animals were injected with benserazide (12.5 mg/kg), followed 20 minutes later by L-
DOPA (25 mg/kg). Control animals were injected with 0.9% saline separated by 20 minutes. 
Mice were tested on the challenging beam traversal task (3 trials) 10 minutes after the 
second injection. A- Number of errors (including slips and misplaced paws) made while 
traversing the beam. B- Number of steps taken to traverse beam. C-Number of errors per 
step taken. D- Time to traverse the beam. (n=8-13). Data shown are means ± SEM. *p<0.05, 
**p<0.01
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Reduced tyrosine hydroxylase (TH) protein levels in MPTP-treated DAT-tg mice. A- 
Immunohistochemical analysis of TH in the striatum of WT and DAT-tg mice treated with 
saline, 15 or 30 mg/kg of MPTP. Representative TH-labeled (black) coronal sections are 
shown. Western blot analysis of TH protein expression in the striatum of B- WT and C- 
DAT-tg mice treated with saline, 15 or 30 mg/kg of MPTP (n=3-4). TH levels were 
corrected for loading using α-tubulin and normalized to WT expression. Data shown are 
means ± SEM. Differences are in comparison to saline-treated animals. * p<0.05, **p<0.01, 
***p<0.001.
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Increased dopaminergic damage in response to MPTP treatment in DAT-tg mice. Relative 
striatal dopamine tissue content is shown for mice treated with saline, 15 or 30 mg/kg of 
MPTP (n=7-9). Levels are represented as percent of WT saline-treated mice. Significant 
differences are in comparison to WT mice at each dose. Data shown are means ± SEM. 
*p<0.05; **p<0.01.
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